Plasminogen activator inhibitor-1 antagonist TM5484 attenuates demyelination and axonal degeneration in a mice model of multiple sclerosis

PLoS ONE

Volumn 10, Issue 4, 2015, Pages

  Pelisch, Nicolas ^a   Dan, Takashi ^a   Ichimura, Atsuhiko ^a   Sekiguchi, Hiroki ^a   Vaughan, Douglas E ^b   Van Ypersele De Strihou, Charles ^c   Miyata, Toshio ^a  

^a TOHOKU UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b NORTHWESTERN UNIVERSITY   (United States)

^c CLINIQUES UNIVERSITAIRES SAINT LUC   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

BRAIN DERIVED NEUROTROPHIC FACTOR; CHOLINE ACETYLTRANSFERASE; COLLAGEN TYPE 4; FINGOLIMOD; INTERLEUKIN 6; METHYLPREDNISOLONE; MONOCYTE CHEMOTACTIC PROTEIN 1; PLASMINOGEN ACTIVATOR DERIVATIVE; PLASMINOGEN ACTIVATOR INHIBITOR 1; PROPRANOLOL; TM 5484; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; VERAPAMIL;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD BRAIN BARRIER; COLLAGEN METABOLISM; CONTROLLED STUDY; DEMYELINATION; DRUG BRAIN LEVEL; DRUG HALF LIFE; EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS; GAIT; HISTOPATHOLOGY; IN VITRO STUDY; INFLAMMATION; MALE; MAXIMUM PLASMA CONCENTRATION; MOTOR COORDINATION; MOUSE; MULTIPLE SCLEROSIS; NERVE FIBER DEGENERATION; NEUROPROTECTION; NONHUMAN; PROTEIN EXPRESSION; TM 5484; TREATMENT RESPONSE; UPREGULATION; ANIMAL; AXON; BIOAVAILABILITY; DEMYELINATING DISEASES; DISEASE MODEL; DRUG EFFECTS; ENCEPHALOMYELITIS, AUTOIMMUNE, EXPERIMENTAL; METABOLISM; NERVE CELL; PARALYSIS; PATHOLOGY; PERMEABILITY; PSYCHOMOTOR PERFORMANCE;

ANIMALIA; MAMMALIA; MUS;

ANIMALS; AXONS; BIOLOGICAL AVAILABILITY; BRAIN-DERIVED NEUROTROPHIC FACTOR; CHOLINE O-ACETYLTRANSFERASE; COLLAGEN TYPE IV; DEMYELINATING DISEASES; DISEASE MODELS, ANIMAL; ENCEPHALOMYELITIS, AUTOIMMUNE, EXPERIMENTAL; MICE; MULTIPLE SCLEROSIS; NEURONS; PARALYSIS; PERMEABILITY; PLASMINOGEN ACTIVATOR INHIBITOR 1; PSYCHOMOTOR PERFORMANCE;

EID: 84928552125     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0124510     Document Type: Article

References (38)

1. Lassmann H, Bruck W, Lucchinetti CF (2007) The immunopathology of multiple sclerosis: an overview. Brain Pathol 17: 210-218. PMID: 17388952
2. Davalos D, Ryu JK, Merlini M, Baeten KM, Le Moan N, Petersen MA, et al. (2012) Fibrinogen-induced perivascular microglial clustering is required for the development of axonal damage in neuroinflammation. Nat Commun 3: 1227. doi: 10.1038/ncomms2230 PMID: 23187627
3. East E, Baker D, Pryce G, Lijnen HR, Cuzner ML, Gveric D (2005) A role for the plasminogen activator system in inflammation and neurodegeneration in the central nervous system during experimental allergic encephalomyelitis. Am J Pathol 167: 545-554. PMID: 16049338
4. Akenami FO, Koskiniemi M, Farkkila M, Vaheri A (1997) Cerebrospinal fluid plasminogen activator inhibitor-1 in patients with neurological disease. J Clin Pathol 50: 157-160. PMID: 9155699
5. Gveric D, Herrera B, Petzold A, Lawrence DA, Cuzner ML (2003) Impaired fibrinolysis in multiple sclerosis: a role for tissue plasminogen activator inhibitors. Brain 126: 1590-1598. PMID: 12805124
6. East E, Gveric D, Baker D, Pryce G, Lijnen HR, Cuzner ML (2008) Chronic relapsing experimental allergic encephalomyelitis (CREAE) in plasminogen activator inhibitor-1 knockout mice: the effect of fibrinolysis during neuroinflammation. Neuropathol Appl Neurobiol 34: 216-230. PMID: 17983428
7. Izuhara Y, Takahashi S, Nangaku M, Takizawa S, Ishida H, Kurokawa K et al. (2008) Inhibition of plasminogen activator inhibitor-1: its mechanism and effectiveness on coagulation and fibrosis. Arterioscler Thromb Vasc Biol 28: 672-677. doi: 10.1161/ATVBAHA.107.157479 PMID: 18239154
8. Izuhara Y, Yamaoka N, Kodama H, Dan T, Takizawa S, Hirayama N, et al. (2010) A novel inhibitor of plasminogen activator inhibitor-1 provides antithrombotic benefits devoid of bleeding effect in nonhuman primates. J Cereb Blood Flow Metab 30: 904-912. doi: 10.1038/jcbfm.2009.272 PMID: 20087372
9. Boe AE, Eren M, Murphy SB, Kamide CE, Ichimura A, Terry D, et al. (2013) Plasminogen activator inhibitor-1 antagonist TM5441 attenuates Nomega-nitro-L-arginine methyl ester-induced hypertension and vascular senescence. Circulation 128: 2318-2324. doi: 10.1161/CIRCULATIONAHA.113.003192 PMID: 24092817
10. Ichimura A, Matsumoto S, Suzuki S, Dan T, Yamaki S, Sato Y, et al. (2013) A small molecule inhibitor to plasminogen activator inhibitor 1 inhibits macrophage migration. Arterioscler Thromb Vasc Biol 33: 935-942. doi: 10.1161/ATVBAHA.113.301224 PMID: 23471233
11. Nakagawa S, Deli MA, Kawaguchi H, Shimizudani T, Shimono T, Kittel A, et al. (2009) A new blood-brain barrier model using primary rat brain endothelial cells, pericytes and astrocytes. Neurochem Int 54: 253-263. doi: 10.1016/j.neuint.2008.12.002 PMID: 19111869
12. Oh J, O'Connor PW(2013) Safety, tolerability, and efficacy of oral therapies for relapsing-remitting multiple sclerosis. CNS Drugs 27: 591-609. doi: 10.1007/s40263-013-0080-z PMID: 23801528
13. Pelletier D, Hafler DA (2012) Fingolimod for multiple sclerosis. N Engl J Med 366: 339-347. doi: 10.1056/NEJMct1101691 PMID: 22276823
14. Lu B, Pang PT, Woo NH (2005) The yin and yang of neurotrophin action. Nat Rev Neurosci 6: 603-614. PMID: 16062169
15. Thone J, Ellrichmann G, Seubert S, Peruga I, Lee DH, Conrad R, et al. (2012) Modulation of autoimmune demyelination by laquinimod via induction of brain-derived neurotrophic factor. Am J Pathol 180: 267-274. doi: 10.1016/j.ajpath.2011.09.037 PMID: 22152994
16. Glynn D, Bortnick RA, Morton AJ (2003) Complexin II is essential for normal neurological function in mice. Hum Mol Genet 12: 2431-2448. PMID: 12915444
17. Wager TT, Chandrasekaran RY, Hou X, Troutman MD, Verhoest PR, Villalobos A, et al. (2010) Defining desirable central nervous system drug space through the alignment of molecular properties, in vitro ADME, and safety attributes. ACS Chem Neurosci 1: 420-434. doi: 10.1021/cn100007x PMID: 22778836
18. Chan J, Ban EJ, Chun KH, Wang S, McQualter J, Bernard C, et al. (2008) Methylprednisolone induces reversible clinical and pathological remission and loss of lymphocyte reactivity to myelin oligodendrocyte glycoprotein in experimental autoimmune encephalomyelitis. Autoimmunity 41: 405-413. doi: 10.1080/08916930802011258 PMID: 18568646
19. Chiba K, Kataoka H, Seki N, Shimano K, Koyama M, Fukunari A, et al. (2011) Fingolimod (FTY720), sphingosine 1-phosphate receptor modulator, shows superior efficacy as compared with interferon-beta in mouse experimental autoimmune encephalomyelitis. Int Immunopharmacol 11: 366-372. doi: 10.1016/j.intimp.2010.10.005 PMID: 20955831
20. Loskutoff DJ, Curriden SA, Hu G, Deng G (1999) Regulation of cell adhesion by PAI-1. APMIS 107: 54-61. PMID: 10190280
21. Gveric D, Hanemaaijer R, Newcombe J, van Lent NA, Sier CF, Cuzner ML (2001) Plasminogen activators in multiple sclerosis lesions: implications for the inflammatory response and axonal damage. Brain 124: 1978-1988. PMID: 11571216
22. Dellas C, Loskutoff DJ (2005) Historical analysis of PAI-1 from its discovery to its potential role in cell motility and disease. Thromb Haemost 93: 631-640. PMID: 15841306
23. Luhder F, Gold R, Flugel A, Linker RA (2013) Brain-derived neurotrophic factor in neuroimmunology: lessons learned from multiple sclerosis patients and experimental autoimmune encephalomyelitis models. Arch Immunol Ther Exp (Warsz) 61: 95-105. doi: 10.1007/s00005-012-0211-0 PMID: 23283517
24. Aharoni R, Vainshtein A, Stock A, Eilam R, From R, Shinder V, et al. (2011) Distinct pathological patterns in relapsing-remitting and chronic models of experimental autoimmune enchephalomyelitis and the neuroprotective effect of glatiramer acetate. J Autoimmun 37: 228-241. doi: 10.1016/j.jaut.2011.06.003 PMID: 21752599
25. Doi Y, Takeuchi H, Horiuchi H, Hanyu T, Kawanokuchi J, Jin S, et al. (2013) Fingolimod phosphate attenuates oligomeric amyloid beta-induced neurotoxicity via increased brain-derived neurotrophic factor expression in neurons. PLoS One 8: e61988. doi: 10.1371/journal.pone.0061988 PMID: 23593505
26. Neumann H (2003) Molecular mechanisms of axonal damage in inflammatory central nervous system diseases. Curr Opin Neurol 16: 267-273. PMID: 12858061
27. Soulika AM, Lee E, McCauley E, Miers L, Bannerman P, Pleasure D. (2009) Initiation and progression of axonopathy in experimental autoimmune encephalomyelitis. J Neurosci 29: 14965-14979. doi: 10.1523/JNEUROSCI.3794-09.2009 PMID: 19940192
28. Norinder U, Haeberlein M (2002) Computational approaches to the prediction of the blood-brain distribution. Adv Drug Deliv Rev 54: 291-313. PMID: 11922949
29. Rossi S, Motta C, Studer V, Barbieri F, Buttari F, Bergami A, et al. (2014) Tumor necrosis factor is elevated in progressive multiple sclerosis and causes excitotoxic neurodegeneration. Mult Scler 20: 304-312. doi: 10.1177/1352458513498128 PMID: 23886826
30. Gur-Wahnon D, Mizrachi T, Maaravi-Pinto FY, Lourbopoulos A, Grigoriadis N, Higazi AA, et al. (2013) The plasminogen activator system: involvement in central nervous system inflammation and a potential site for therapeutic intervention. J Neuroinflammation 10: 124. doi: 10.1186/1742-2094-10-124 PMID: 24120085
31. Neumann H, Medana IM, Bauer J, Lassmann H (2002) Cytotoxic T lymphocytes in autoimmune and degenerative CNS diseases. Trends Neurosci 25: 313-319. PMID: 12086750
32. Redford EJ, Kapoor R, Smith KJ (1997) Nitric oxide donors reversibly block axonal conduction: demyelinated axons are especially susceptible. Brain 120 (Pt 12): 2149-2157. PMID: 9448570
33. van Horssen J, Bo L, Dijkstra CD, de Vries HE (2006) Extensive extracellular matrix depositions in active multiple sclerosis lesions. Neurobiol Dis 24: 484-491. PMID: 17005408
34. van Horssen J, Bo L, Vos CM, Virtanen I, de Vries HE (2005) Basement membrane proteins in multiple sclerosis-associated inflammatory cuffs: potential role in influx and transport of leukocytes. J Neuropathol Exp Neurol 64: 722-729. PMID: 16106221
35. Thoenen H (1995) Neurotrophins and neuronal plasticity. Science 270: 593-598. PMID: 7570017
36. Deogracias R, Yazdani M, Dekkers MP, Guy J, Ionescu MC, Vogt KE, et al. (2012) Fingolimod, a sphingosine-1 phosphate receptor modulator, increases BDNF levels and improves symptoms of a mouse model of Rett syndrome. Proc Natl Acad Sci U S A 109: 14230-14235. doi: 10.1073/pnas.1206093109 PMID: 22891354
37. Shin T, Ahn M, Matsumoto Y (2012) Mechanism of experimental autoimmune encephalomyelitis in Lewis rats: recent insights from macrophages. Anat Cell Biol 45: 141-148. doi: 10.5115/acb.2012.45.3.141 PMID: 23094201
38. Wiendl H, Hohlfeld R (2009) Multiple sclerosis therapeutics: unexpected outcomes clouding undisputed successes. Neurology 72: 1008-1015. doi: 10.1212/01.wnl.0000344417.42972.54 PMID: 19289741